Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Diluted Average) (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Shares Outstanding (Diluted Average) for 15 consecutive years, with $27.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) fell 1.09% year-over-year to $27.7 million, compared with a TTM value of $27.7 million through Sep 2025, down 1.09%, and an annual FY2024 reading of $27.3 million, up 2.71% over the prior year.
  • Shares Outstanding (Diluted Average) was $27.7 million for Q3 2025 at Fennec Pharmaceuticals, roughly flat from $27.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $31.1 million in Q1 2024 and bottomed at $1.6 million in Q2 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $25.4 million, with a median of $26.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 94.13% in 2024, then surged 1679.7% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $26.0 million in 2021, then grew by 1.03% to $26.3 million in 2022, then grew by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then increased by 1.53% to $27.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for FENC at $27.7 million in Q3 2025, $27.6 million in Q2 2025, and $27.6 million in Q1 2025.